Trade-Ideas: Sealed Air (SEE) Is Today's New Lifetime High Stock

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Sealed Air ( SEE) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Sealed Air as such a stock due to the following factors:

  • SEE has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $115.2 million.
  • SEE has traded 57,882 shares today.
  • SEE is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in SEE with the Ticky from Trade-Ideas. See the FREE profile for SEE NOW at Trade-Ideas

More details on SEE:

Sealed Air Corporation provides food safety and security, facility hygiene, and product protection solutions worldwide. The stock currently has a dividend yield of 1.1%. SEE has a PE ratio of 36. Currently there are 3 analysts that rate Sealed Air a buy, no analysts rate it a sell, and 5 rate it a hold.

The average volume for Sealed Air has been 1.7 million shares per day over the past 30 days. Sealed Air has a market cap of $10.1 billion and is part of the consumer goods sector and consumer non-durables industry. The stock has a beta of 1.77 and a short float of 2.6% with 2.21 days to cover. Shares are up 13% year-to-date as of the close of trading on Wednesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Five S&P 500 Boards Have No Women as Gender Balance Growth Stalls

Dow Losses Extend Into Day Eight; Longest Losing Streak in Nearly Six Years

Stocks Mixed as Wall Street Shakes Off Worries Over Trumpcare's Defeat

Dow Drops Triple Digits as Trumpcare Fails, Worries Rise Over President's Agenda

Stock Futures Plummet as Trumpcare's Failure Raises Doubts About What's Next